Tumor Mutational Burden Shapes Success and Resistance in Cancer Immunotherapy.

Abstract excerpt

Immunotherapy, particularly immune checkpoint blockade, has transformed cancer treatment, yet durable responses remain limited to a subset of patients and cancer types. Many tumors exhibit innate resistance or acquire resistance through immune evasion or neoantigen editing. A central factor in shaping these outcomes is the tumor mutational burden. However, cancer mutations can enhance or impair both cellular...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Drug Resistance, Neoplasm
• Share to Immunotherapy
• Share to Models, Biological